Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on June 30, 2025
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
GlobeNewswire
·
June 30, 2025
CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index as part of the reconstitution of the …
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 30, 2025
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic …
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
GlobeNewswire
·
June 30, 2025
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined …
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire
·
June 30, 2025
Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from the Cancer Prevention …
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
GlobeNewswire
·
June 30, 2025
BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programs Transaction monetizes 60% of BridgeBio’s European royalties on the first $500 …
Bimergen Energy Enhances Shareholder Value by Canceling 25.1% of Its Outstanding Common Stock
GlobeNewswire
·
June 30, 2025
Newport Beach, CA, June 30, 2025 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [OTCQB: BESS], (“the Company” or “Bimergen”), a developer of utility-scale battery energy storage projects and an independent power provider, today announced the proceeding of …
FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY HAS BEEN APPROVED TO RECEIVE SCOTT COUNTY OPIOID ABATEMENT FUNDS
GlobeNewswire
·
June 30, 2025
WEST PALM BEACH, FLORIDA, June 30, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has been approved to receive Scott …
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
GlobeNewswire
·
June 30, 2025
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”), the six-month radiographic progression free survival (“rPFS”) rate was 66% • In a …
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
GlobeNewswire
·
June 30, 2025
--Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC) --No other concerns stated, including pre-clinical, clinical, or safety data --The Company identified …
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
GlobeNewswire
·
June 30, 2025
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA …
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 30, 2025
CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with …
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
GlobeNewswire
·
June 30, 2025
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of …
U.S. Department of Health and Human Services Designates Four Nutrients of Public Health Concern Validating Glucose Health, Inc. (OTC: GLUC) Patent Pending Soluble Fiber-Based Nutrition Formulation
GlobeNewswire
·
June 30, 2025
BENTONVILLE, Ark., June 30, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a publicly traded company specializing in diabetic nutrition and soluble fiber-based nutrition products, today commented on the U.S. Department of Health and Human …
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
GlobeNewswire
·
June 30, 2025
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for …
PathAI Receives FDA Clearance for AISight® Dx Platform for Primary Diagnosis
GlobeNewswire
·
June 30, 2025
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its …
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
GlobeNewswire
·
June 30, 2025
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients — — Consistent benefit regardless of …
Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration
GlobeNewswire
·
June 30, 2025
THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- In a strategic move to improve patient outcomes in breast cancer, Affidea, a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud …
Affidea-Gruppe wählt b-rayZ als bevorzugten KI-Partner für die Brustbildgebung und geht strategische Zusammenarbeit ein
GlobeNewswire
·
June 30, 2025
DEN HAAG, Niederlande, June 30, 2025 (GLOBE NEWSWIRE) -- Im Rahmen einer strategischen Maßnahme zur Verbesserung der Behandlungsergebnisse bei Brustkrebs gibt Affidea, ein führender paneuropäischer Betreiber von kommunalen Polikliniken sowie Anbieter von …
El Grupo Affidea elige a b-rayZ como colaborador preferente en IA para el diagnóstico mamario por imagen en una asociación estratégica
GlobeNewswire
·
June 30, 2025
LA HAYA, Países Bajos, June 30, 2025 (GLOBE NEWSWIRE) -- En una acción estratégica para mejorar los resultados de las pacientes con cáncer de mama, Affidea, proveedor paneuropeo líder en policlínicas comunitarias, servicios especializados y diagnóstico …
Le groupe Affidea choisit b-rayZ comme partenaire d’IA privilégié en imagerie mammaire, marquant ainsi le début d’une collaboration stratégique
GlobeNewswire
·
June 30, 2025
LA HAYE, Pays-Bas, 30 juin 2025 (GLOBE NEWSWIRE) -- Dans une démarche stratégique visant à améliorer les résultats des patientes atteintes d’un cancer du sein, Affidea, l’un des principaux prestataires paneuropéens de polycliniques de proximité, de …